COVID-19 Tech Collaborations: Adaptive And Microsoft Map Immune System Responses

A two and half year-old partnership between Adaptive Biotechnologies and Microsoft that began with a focus on Lyme disease has transitioned to mapping immune responses to the SARS-CoV-2 virus. By identifying and matching T cell receptors to antigens associated with the virus – and leveraging the power of machine learning – the companies hope to improve COVID-19 vaccine development, locate potential antibodies for drug development and create better, more sensitive diagnostics.

technology collaboration

Sequencing immune cell responses to diseases and mapping those responses to the specific antigens that triggered them, could help prevent the spread of future infectious diseases. “The human immune system is the best detection mechanism there is,” said Harlan Robins, chief scientific officer and co-founder of Adaptive Biotechnologies Corporation. Adaptive’s ongoing partnership with Microsoft, which is producing results on differing immune responses to COVID-19, is an example of how technology sector tools, specifically machine learning, can be leveraged in the fight against disease. “We have warning systems for viral computer threats, we just don't have any for actual viral threats,” said Robins.

The successful sequencing of the human genome at the turn of the millennium ushered in a new era of genomic...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from COVID-19

Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff

 

Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.

COVID To GLP-1: Catalent Plants Ride With Novo To Next Public Health Crisis

 
• By 

A complex transformation is underway as client proposes to acquire CDMO facilities that vaccinated the world against the COVID-19 pandemic for pivot to the obesity epidemic.

Outlook 2024: Biopharma Embraces New Markets And New Tech

 

New markets, a patent cliff, an M&A rebound and clinical trial catalysts. How will it all play out for the biopharma sector in 2024? 

After All The Layoffs, Is Biopharma’s Headcount Still Growing?

 

While biotech layoffs and big pharma restructuring dominate the news in 2023, the sector’s job market remains buoyant.

More from In Vivo

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By 

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By 

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By 

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.